Biologics Regulatory Affairs Outsourcing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Service (Regulatory Consulting, Legal Representation, Regulatory Writing & Publishing, Product Registration & Clinical, Trial Applications, Regulatory Submissions, Regulatory Operations, and Others), By Phase (Preclinical and Clinical), By Modality (Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cell & Gene Therapies, Biosimilars, and Others), By Region & Competition, 2021-2031F

May 2026 | 180 pages | ID: B6A1429CC236EN
TechSci Research

Abstracts

The Global Biologics Regulatory Affairs Outsourcing Market is projected to expand from USD 2.59 Billion in 2025 to USD 4.26 Billion by 2031, exhibiting an 8.65% Compound Annual Growth Rate. This market encompasses the delegation of regulatory compliance, submission processes, and lifecycle management for biological products to external, specialized providers. Key factors driving this growth include the increasing complexity of global regulatory frameworks, the imperative for cost efficiency, and the strategic reallocation of internal resources towards fundamental drug discovery efforts. For instance, the European research-based pharmaceutical industry invested approximately €55,000 million in R&D in Europe in 2024, as per EFPIA, generating extensive development activities that require substantial external regulatory support. However, a notable challenge hindering market expansion is the elevated risk associated with data confidentiality and intellectual property theft. Given the proprietary and high-value nature of biological formulations, biopharmaceutical developers often hesitate to entrust sensitive technical data to third-party partners, thereby restricting the scope of outsourced tasks to administrative functions rather than comprehensive lifecycle management.

Market Driver

The increasing complexity of global regulatory frameworks serves as a primary driver for the Global Biologics Regulatory Affairs Outsourcing Market, prompting biopharmaceutical firms to seek specialized external support. Regulatory bodies globally are enforcing more stringent standards for product safety, efficacy, and quality, leading to a rise in submission volumes and more intricate compliance demands. Companies must manage a continuously evolving set of guidelines, requiring substantial resources for the growing number of approval applications and ongoing lifecycle maintenance. For example, the European Medicines Agency recommended 114 medicines for marketing authorization in 2024, as per its 'Human medicines in 2024' report (January 2025), illustrating the increasing regulatory burden on internal teams. Concurrently, the rapid expansion of the global biosimilars market is significantly influencing regulatory requirements, necessitating outsourced expertise to manage expedited approval processes and interchangeability studies. With the expiration of patents for major biologics, the surge in biosimilar development mandates accurate regulatory strategies to prove biosimilarity without redundant clinical trials. This segment's growth generates a specific need for consultants skilled in comparative analytical and clinical data. In 2024, there were 18 FDA approvals of biosimilar products, as reported by Goodwin Procter LLP in January 2025, indicating strong momentum. Additionally, the FDA's 'Novel Drug Approvals for 2024' report (January 2025) noted 16 new biological therapeutics approved, emphasizing the need for robust regulatory lifecycle management that fuels this market.

Market Challenge

A significant impediment to the growth of the Global Biologics Regulatory Affairs Outsourcing Market is the elevated risk concerning data confidentiality and intellectual property theft. Biologic drug development heavily depends on proprietary data, such as intricate cell line attributes and manufacturing trade secrets. Entrusting this sensitive information to external regulatory affairs providers exposes companies to cyber risks and the potential misappropriation of trade secrets. Biopharmaceutical developers are acutely conscious that any breach could undermine their competitive advantage, particularly within the aggressive biosimilar market where the secrecy of formulations is crucial. The reluctance to outsource stems from the substantial financial value assigned to these intellectual property assets, making the cost of a potential security failure prohibitively high. PhRMA reported in 2025 that biopharmaceutical companies invested over $12 million for each patent granted by the United States Patent and Trademark Office, underscoring the considerable capital outlay required to secure a single protected asset. Consequently, the apprehension of losing such valuable investments compels companies to keep strategic regulatory activities in-house. This cautious approach directly restricts market expansion by limiting external vendors to lower-value administrative tasks instead of comprehensive lifecycle management.

Market Trends

A high-value niche emerging within the outsourcing market is specialized support for Cell and Gene Therapy (CGT) approval pathways, which differs significantly from conventional biologics compliance. CGTs demand innovative regulatory strategies, including intricate chain-of-identity tracking, extended patient follow-up protocols, and negotiations for expedited pathways like RMAT or PRIME. Biopharmaceutical innovators are increasingly engaging external experts to navigate these novel areas where internal experience is often lacking and precise logistics are crucial for approval. This segment is expected to grow rapidly as the CGT pipeline progresses from clinical development to commercialization. The Alliance for Regenerative Medicine's 'State of the Industry Briefing' (January 2025) indicates that the sector is maturing substantially, with "75 per cent of the global revenue comes from less than 10 products, that'll move to 50 products by 2030," suggesting a significant increase in commercial-stage regulatory maintenance needs requiring scalable external support. Concurrently, the adoption of artificial intelligence to enhance regulatory submission efficiency is fundamentally transforming the service delivery approach of outsourcing vendors. Regulatory bodies are demanding quicker turnarounds and improved data accuracy, compelling providers to implement generative AI tools for automating labor-intensive tasks such as hyperlinking, dossier formatting, and consistency checks across documents. This technological advancement enables vendors to deliver cost-effective solutions that significantly minimize manual errors and accelerate submission timelines, providing a competitive edge over traditional manual processes. A survey by ArisGlobal (November 2024) on AI adoption in regulatory affairs revealed that "ninety-six percent of respondents agree that AI is essential to resolving regulatory bottlenecks," driving a clear preference for tech-enabled outsourcing partners capable of utilizing these advanced digital capabilities.

Key Market Players

• Lonza Group AG Ltd
• WuXi AppTec Co., Ltd.
• Freyr solutions
• Catalent Inc.
• ICON Plc
• Charles River Laboratories International, Inc.
• Laboratory Corporation of America Holdings
• Medpace, Inc.
• Iqvia Holdings Inc.
• Syneos Health

Report Scope

In this report, the Global Biologics Regulatory Affairs Outsourcing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Biologics Regulatory Affairs Outsourcing Market, By Service
• Regulatory Consulting
• Legal Representation
• Regulatory Writing & Publishing
• Product Registration & Clinical
• Trial Applications
• Regulatory Submissions
• Regulatory Operations
• Others
• Biologics Regulatory Affairs Outsourcing Market, By Phase
• Preclinical
• Clinical
• Biologics Regulatory Affairs Outsourcing Market, By Modality
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Cell & Gene Therapies
• Biosimilars
• Others
• Biologics Regulatory Affairs Outsourcing Market, By Region
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biologics Regulatory Affairs Outsourcing Market.

Available Customizations:

Global Biologics Regulatory Affairs Outsourcing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL BIOLOGICS REGULATORY AFFAIRS OUTSOURCING MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Service (Regulatory Consulting, Legal Representation, Regulatory Writing & Publishing, Product Registration & Clinical, Trial Applications, Regulatory Submissions, Regulatory Operations, Others)
  5.2.2. By Phase (Preclinical, Clinical)
  5.2.3. By Modality (Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cell & Gene Therapies, Biosimilars, Others)
  5.2.4. By Region
  5.2.5. By Company (2025)
5.3. Market Map

6. NORTH AMERICA BIOLOGICS REGULATORY AFFAIRS OUTSOURCING MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Service
  6.2.2. By Phase
  6.2.3. By Modality
  6.2.4. By Country
6.3. North America: Country Analysis
  6.3.1. United States Biologics Regulatory Affairs Outsourcing Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Service
      6.3.1.2.2. By Phase
      6.3.1.2.3. By Modality
  6.3.2. Canada Biologics Regulatory Affairs Outsourcing Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Service
      6.3.2.2.2. By Phase
      6.3.2.2.3. By Modality
  6.3.3. Mexico Biologics Regulatory Affairs Outsourcing Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Service
      6.3.3.2.2. By Phase
      6.3.3.2.3. By Modality

7. EUROPE BIOLOGICS REGULATORY AFFAIRS OUTSOURCING MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Service
  7.2.2. By Phase
  7.2.3. By Modality
  7.2.4. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Biologics Regulatory Affairs Outsourcing Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Service
      7.3.1.2.2. By Phase
      7.3.1.2.3. By Modality
  7.3.2. France Biologics Regulatory Affairs Outsourcing Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Service
      7.3.2.2.2. By Phase
      7.3.2.2.3. By Modality
  7.3.3. United Kingdom Biologics Regulatory Affairs Outsourcing Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Service
      7.3.3.2.2. By Phase
      7.3.3.2.3. By Modality
  7.3.4. Italy Biologics Regulatory Affairs Outsourcing Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Service
      7.3.4.2.2. By Phase
      7.3.4.2.3. By Modality
  7.3.5. Spain Biologics Regulatory Affairs Outsourcing Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Service
      7.3.5.2.2. By Phase
      7.3.5.2.3. By Modality

8. ASIA PACIFIC BIOLOGICS REGULATORY AFFAIRS OUTSOURCING MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Service
  8.2.2. By Phase
  8.2.3. By Modality
  8.2.4. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Biologics Regulatory Affairs Outsourcing Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Service
      8.3.1.2.2. By Phase
      8.3.1.2.3. By Modality
  8.3.2. India Biologics Regulatory Affairs Outsourcing Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Service
      8.3.2.2.2. By Phase
      8.3.2.2.3. By Modality
  8.3.3. Japan Biologics Regulatory Affairs Outsourcing Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Service
      8.3.3.2.2. By Phase
      8.3.3.2.3. By Modality
  8.3.4. South Korea Biologics Regulatory Affairs Outsourcing Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Service
      8.3.4.2.2. By Phase
      8.3.4.2.3. By Modality
  8.3.5. Australia Biologics Regulatory Affairs Outsourcing Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Service
      8.3.5.2.2. By Phase
      8.3.5.2.3. By Modality

9. MIDDLE EAST & AFRICA BIOLOGICS REGULATORY AFFAIRS OUTSOURCING MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Service
  9.2.2. By Phase
  9.2.3. By Modality
  9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Biologics Regulatory Affairs Outsourcing Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Service
      9.3.1.2.2. By Phase
      9.3.1.2.3. By Modality
  9.3.2. UAE Biologics Regulatory Affairs Outsourcing Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Service
      9.3.2.2.2. By Phase
      9.3.2.2.3. By Modality
  9.3.3. South Africa Biologics Regulatory Affairs Outsourcing Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Service
      9.3.3.2.2. By Phase
      9.3.3.2.3. By Modality

10. SOUTH AMERICA BIOLOGICS REGULATORY AFFAIRS OUTSOURCING MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Service
  10.2.2. By Phase
  10.2.3. By Modality
  10.2.4. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Biologics Regulatory Affairs Outsourcing Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Service
      10.3.1.2.2. By Phase
      10.3.1.2.3. By Modality
  10.3.2. Colombia Biologics Regulatory Affairs Outsourcing Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Service
      10.3.2.2.2. By Phase
      10.3.2.2.3. By Modality
  10.3.3. Argentina Biologics Regulatory Affairs Outsourcing Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Service
      10.3.3.2.2. By Phase
      10.3.3.2.3. By Modality

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL BIOLOGICS REGULATORY AFFAIRS OUTSOURCING MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. Lonza Group AG Ltd
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. WuXi AppTec Co., Ltd.
15.3. Freyr solutions
15.4. Catalent Inc.
15.5. ICON Plc
15.6. Charles River Laboratories International, Inc.
15.7. Laboratory Corporation of America Holdings
15.8. Medpace, Inc.
15.9. Iqvia Holdings Inc.
15.10. Syneos Health

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER